HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

@article{Valabrega2010HER2positiveBC,
  title={HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib},
  author={Giorgio Valabrega and Sonia Capellero and Giuliana Cavalloni and Gianluca Zaccarello and Annalisa Petrelli and Giorgia Migliardi and Andrea Milani and Caterina Peraldo-Neia and Loretta Gammaitoni and Anna Sapino and Carla Pecchioni and Aldo Moggio and Silvia Giordano and Massimo Aglietta and Filippo Montemurro},
  journal={Breast Cancer Research and Treatment},
  year={2010},
  volume={130},
  pages={29-40}
}
Trastuzumab has changed the prognosis of HER2 positive breast cancers. Despite this progress, resistance to trastuzumab occurs in most patients. Newer anti-HER2 therapies, like the dual tyrosine-kinase inhibitor (TKI) lapatinib, show significant antitumor activity, indicating that HER2 can be still exploited as a target after trastuzumab failure. However, since a high proportion of patients fail to respond to these alternative strategies, it is possible that cell escape from HER2 targeting may… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

a german breast group 26/breast international group 03-05 study

  • G von Minckwitz, A du Bois, M Schmidt, N Maass, T Cufer, cancer de Jongh FE et al Trastuzumab beyond progression i breast
  • J Clin Oncol 27:1999–2006 Breast Cancer Res…
  • 2011
1 Excerpt

Sorafenib (BAY 43-9006) downregulates survivin protein level by inhibition of translation in human NSCLC cells

  • K Eun-Sung, S Sung-Keum, J Hyeon-Ok, P. In-Chul
  • Ephar congress Abstract
  • 2008
2 Excerpts

HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer

  • H Burstein, A Awada, R Badwe, L Dirix, A Tan, S Jacod
  • In Breast Cancer Research and Treatment,
  • 2007

Similar Papers

Loading similar papers…